Piper Jaffray to Host 2nd Annual London Health Care Conference

LONDON, June 13  /PRNewswire-FirstCall/ -- Piper Jaffray will host its 2nd Annual London Health Care Conference June 20-21, 2007, in London. The conference will feature presentations from more than 70 European and U.S. top growing biopharmaceutical and medical technology companies.

"There are tremendous opportunities in the biopharmaceutical and medical technology industries for investors," said Sam Fazeli, deputy head of European Research at Piper Jaffray Ltd. "We view the sector to have significant possibilities for growth and expansion and look forward to hosting some of the leading and most dynamic growth companies to present to our clients first-hand."

Companies scheduled to present include: Acambis Plc; Acorda Therapeutics, Inc.; AGI Therapeutics; Alexza Pharmaceuticals, Inc.; Alizyme Plc; ALK-Abello A/S; Allergy Therapeutics; Alnylam Pharmaceuticals, Inc.; Antisoma Plc; Applied Biosystems Group; Ardana Plc; Ark Therapeutics Plc; Arpida; Axis-Shield; Basilea Pharmaceutica; Bavarian Nordic; BioAlliance Pharma SA; Biocompatibles Plc; BioXell; Bristol-Myers Squibb Company; BTG plc; Celera Group; Celgene Corporation; Centene Corporation; Cerner Corporation; Corin Group Plc; Curalogic A/S; Cytori Therapeutics, Inc.; Cytos Biotechnology AG; Cytyc Corporation; DexCom, Inc.; Emageon Inc.; Entelos; Evotec AG; Exelixis, Inc.; Galapagos NV; Genmab A/S; GPC Biotech AG; Gyrus Group Plc; Immucor, Inc.; Incyte Corporation; Infinity Pharmaceuticals, Inc.; Innate Pharma SA; Integra LifeSciences Holdings Corporation; Inion OY; Intercell AG; Intercytex Group Plc; Jerini AG; Kyphon Inc.; LifeCycle Pharma A/S; Lipoxen Plc; NeuroSearch A/S; Newron Pharma SpA; NicOx SA; OncoMethylome Sciences SA; Optimer Pharmaceuticals, Inc.; Oxford Biomedica; ProStrakan Group Plc; Protherics plc; PuriCore plc; Qiagen NV; Renovo Group; Santhera Pharmaceuticals; Silence Therapeutics Plc; Sinclair Pharmaceuticals; SkyePharma; Smith & Nephew plc; Spacelabs Healthcare, Inc; Speedel Holding AG; SuperGen, Inc.; Third Wave Technologies, Inc.; Thrombogenics NV; TiGenix; Tissue Science Laboratories Plc; TopoTarget A/S; Vectura Group Plc.; Vernalis Plc; Vical Incorporated; Vital Images, Inc.; and WILEX AG.

Company and investor participation in the Piper Jaffray London Health Care Conference is by invitation only. Clients interested in attending should contact their Piper Jaffray representative.

About Piper Jaffray

Piper Jaffray Companies is a leading, international middle market investment bank and institutional securities firm, serving the needs of middle market corporations, private equity groups, public entities, nonprofit clients and institutional investors. Founded in 1895, Piper Jaffray provides a comprehensive set of products and services, including equity and debt capital markets products; public finance services; mergers and acquisitions advisory services; high-yield and structured products; institutional equity and fixed-income sales and trading; and equity and high-yield research. With headquarters in Minneapolis, Piper Jaffray has 25 offices across the United States and international locations in London and Shanghai.

The firm's UK operating subsidiary, Piper Jaffray Ltd., is registered in England, no. 3846990, and its registered office is 7 Pilgrim St, London EC4V 6LB.  Piper Jaffray Ltd. is authorised and regulated by the Financial Services Authority, entered on the FSA's register, http://www.fsa.gov.uk/register/home.do, no.191657 and is a member of the London Stock Exchange.

Piper Jaffray & Co. is the firm's principal operating subsidiary. (NYSE: PJC; http://www.piperjaffray.com/ )

For additional disclosure information please see http://www.piperjaffray.com/researchdisclosures.

Since 1895. Member SIPC and NYSE. 

DATASOURCE: Piper Jaffray



CONTACT:  Rob Litt, Public Relations and Communications of Piper Jaffray

& Co., [phone]



Web site:  http://www.piperjaffray.com/ 

Copyright